About 19 results found for searched term "Btk inhibitor 2" (0.141 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M8887 | Btk inhibitor 2 | BTK |
| BGB-3111 | ||
| Btk inhibitor 2 (BGB-3111) is a Brutons tyrosine kinase (BTK) inhibitor. | ||
| M20631 | BTK inhibitor 1 (Compound 27) | BTK |
| BTK inhibitor 1 (compound 27) is an inhibitor of BTK with an IC50 of 0.11 nM for Btk and inhibits B cell activation in hWB with an IC50 of 2 nM. | ||
| M43813 | NX-2127 | BTK |
| NX-2127 is an orally active, potent BTK inhibitor that induces degradation of mutant BTKC481S in cells, as well as inhibits the proliferation of BTKC481S mutant TMD8 cells. In addition, NX-2127 stimulates T cell activation and increases IL-2 production in primary human T cells. | ||
| M5162 | ONO-4059 analogue | BTK |
| ONO-4059 analogue is the analog of ONO-4059, ONO-4059 is a highly potent and selective Btk inhibitor with IC50 of 23.9 nM. | ||
| M5257 | ONO-4059 hydrochloride | BTK |
| GS-4059 hydrochloride; Tirabrutinib hydrochloride | ||
| ONO-4059 (GS-4059) hydrochloride is highly potent and selective BTK inhibitor with an IC50 of 2.2 nM. | ||
| M5333 | Tirabrutinib | BTK |
| ONO-4059; GS-4059 | ||
| Tirabrutinib (ONO-4059) is a highly selective, orally bioavailable BTK inhibitor with a potency (IC50) of 2.2 nM. | ||
| M6907 | (Z)-LFM-A13 | BTK |
| LFM-A13 is a specific Bruton's tyrosine kinase (BTK) inhibitor with IC50 of 2.5 μM. | ||
| M7536 | BMS-935177 | BTK |
| BMS-935177 is a potent, reversible Bruton's Tyrosine Kinase (BTK) inhibitor with an IC50 value of 2.8 nM and demonstrates good kinase selectivity. It is more potent against BTK than other kinase, including the other Tec family kinases (TEC, BMX, ITK, and TXK) over which the compound is between 5- and 67-fold selective. | ||
| M9889 | PCI-29732 | BTK |
| PCI29732 | ||
| PCI-29732 is a potent, reversible BTK inhibitor with Kiapp values of 8.2, 4.6, and 2.5 nM for BTK, Lck, and Lyn, respectively, and has only modest inhibitory activity against Itk, another Tec family kinase. In addition, PCI 29732 inhibits the function of ABCG2 by competitively binding to the ATP binding site of ABCG2. | ||
| M10500 | Remibrutinib | BTK |
| LOU064 | ||
| Remibrutinib (LOU064) is a potentially best-in-class "best-in-class" orally active bruton tyrosine kinase (BTK) inhibitor with an IC50 value of 1 nM and an IC50 value of 0.23 μM for inhibition of BTK activity in blood. Remibrutinib can be used to study chronic urticaria (CU). | ||
| M10896 | Vecabrutinib | BTK |
| SNS-062 | ||
| Vecabrutinib (SNS-062) is a potent, non-covalent BTK and ITK inhibitor,Kd The values are 0.3 nM and 2.2 nM, respectively. Vecabrutinib for ITK IC50 The value is 24 nM. | ||
| M11431 | Poseltinib | BTK |
| HM71224; LY3337641 | ||
| Poseltinib is an orally active, selective, irreversible small-molecule Bruton tyrosine kinase (BTK) inhibitor with an IC50 of 1.95 nM and 0.3, 2.3, and 2.4 fold selective action against BMX, TEC, and TXK, respectively. Poseltinib covalently binds to the active site of BTK (cysteine 481 residue) and effectively inhibits B cell receptor (BCR), Fc receptor (FcR), and Toll-like receptor (TLR) mediated signaling. | ||
| M28212 | G-744 | BTK |
| G-744 is a highly potent, selective and orally active Btk inhibitor with an IC50 of 2 nM. G-744 is metabolically stable, well tolerated and efficacious to treat arthritis. | ||
| M28664 | PF-06250112 | BTK |
| PF-06250112 is a potent, highly selective, orally bioavailable BTK inhibitor with an IC50 of 0.5 nM, shows inhibitory effect toward BMX nonreceptor tyrosine kinase and TEC with IC50s of 0.9 nM and 1.2 nM, respectively. | ||
| M28957 | BTK inhibitor 17 | BTK |
| BTK inhibitor 17 is a potent and orally active irreversible BTK inhibitor with an IC50 of 2.1 nM. BTK inhibitor 17 can be used for rheumatoid arthritis research. | ||
| M29210 | CHMFL-BTK-01 | BTK |
| CHMFL-BTK-01 (compound 9) is a highly selective irreversible BTK inhibitor, with an IC50 of 7 nM. CHMFL-BTK-01 (compound 9) potently inhibited BTK Y223 auto-phosphorylation. | ||
| M29480 | BGB-8035 | BTK |
| BGB-8035 is an orally active, highly selective bruton's tyrosine kinase (BTK) inhibitor with IC50s of 1.1 nM, 99 nM, 621 nM for BTK, TEC, EGFR, respectively. BGB-8035 has antitumor and anti-arthritis activity. BGB-8035 has the potential for B-cell malignancies and autoimmune diseases research. | ||
| M30952 | Lck inhibitor 2 | Src-bcr-Abl |
| Lck inhibitor 2 is a bis-anilinopyrimidine inhibitor of tyrosine kinases including LCK, BTK, LYN, SYK, and TXK. The IC50 values are 13nM, 9nM, 3nM, 26nM and 2nM for Lck, Btk, Lyn, Btk and Txk respectively IC50 Value: 13 nM(Lck) [1] Target: Src family kinase Lck inhibitor 2(Compound 9) inhibited 48 kinases with %control < 1 (33 of them tyrosine kinases, almost half of the 71 tyrosine kinases in the panel). A further 27 kinases were bound with %control < 10. Kd values for 16 kinases were determined and found to be below 100 nM. These included TXK (10 nM). | ||
| M43477 | BTK-IN-27 | BTK |
| BTK-IN-27 is a BTK inhibitor (IC50: 0.2 nM). | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
